MannKind Corp (NASDAQ:MNKD) — Market Cap & Net Worth
Market Cap & Net Worth: MannKind Corp (MNKD)
MannKind Corp (NASDAQ:MNKD) has a market capitalization of $1.13 Billion ($1.13 Billion) as of June 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8496 globally and #2407 in its home market, demonstrating a 3.98% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MannKind Corp's stock price $3.66 by its total outstanding shares 308950166 (308.95 Million). Review MannKind Corp balance sheet liabilities to assess the company's total debt and financial obligations.
MannKind Corp Market Cap History: 2015 to 2026
MannKind Corp's market capitalization history from 2015 to 2026. Data shows change from $2.24 Billion to $1.13 Billion (-13.35% CAGR).
Index Memberships
MannKind Corp is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.08 Trillion | 0.10% | #22 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.05% | #236 of 976 |
|
NASDAQ Composite
IXIC
|
$40.95 Trillion | 0.00% | #906 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.07% | #137 of 263 |
Weight: MannKind Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MannKind Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MannKind Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.02x
MannKind Corp's market cap is 5.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
298.78x
MannKind Corp's market cap is 298.78 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $983.54 Million | $174.76 Million | $125.66 Million | 5.63x | 7.83x |
| 2017 | $716.76 Million | $11.74 Million | -$117.33 Million | 61.03x | N/A |
| 2018 | $327.49 Million | $27.86 Million | -$86.97 Million | 11.76x | N/A |
| 2019 | $398.55 Million | $63.04 Million | -$51.90 Million | 6.32x | N/A |
| 2020 | $967.01 Million | $65.14 Million | -$57.24 Million | 14.84x | N/A |
| 2021 | $1.35 Billion | $75.44 Million | -$80.93 Million | 17.90x | N/A |
| 2022 | $1.63 Billion | $99.77 Million | -$87.40 Million | 16.32x | N/A |
| 2023 | $1.12 Billion | $198.96 Million | -$11.94 Million | 5.65x | N/A |
| 2024 | $1.99 Billion | $285.50 Million | $27.59 Million | 6.96x | 72.01x |
| 2025 | $1.75 Billion | $348.97 Million | $5.86 Million | 5.02x | 298.78x |
Competitor Companies of MNKD by Market Capitalization
Companies near MannKind Corp in the global market cap rankings as of June 16, 2026.
Key companies related to MannKind Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #438 globally with a market cap of $63.06 Billion USD.
- UCB SA (BR:UCB): Ranked #544 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #563 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $444.93 |
| #438 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.06 Billion | $612.14 |
| #544 | UCB SA | BR:UCB | $49.68 Billion | €274.90 |
| #563 | Argen-X | BR:ARGX | $47.14 Billion | €783.60 |
MannKind Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, MannKind Corp's market cap moved from $2.24 Billion to $ 1.13 Billion, with a yearly change of -13.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.13 Billion | -35.45% |
| 2025 | $1.75 Billion | -11.82% |
| 2024 | $1.99 Billion | +76.65% |
| 2023 | $1.12 Billion | -30.93% |
| 2022 | $1.63 Billion | +20.59% |
| 2021 | $1.35 Billion | +39.62% |
| 2020 | $967.01 Million | +142.64% |
| 2019 | $398.55 Million | +21.70% |
| 2018 | $327.49 Million | -54.31% |
| 2017 | $716.76 Million | -27.12% |
| 2016 | $983.54 Million | -56.09% |
| 2015 | $2.24 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 15th, 2026 the market cap of MannKind Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.13 Billion USD |
| MoneyControl | $1.13 Billion USD |
| MarketWatch | $1.13 Billion USD |
| marketcap.company | $1.13 Billion USD |
| Reuters | $1.13 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve… Read more